Susquehanna Fundamental Investments LLC Buys New Position in Exelixis, Inc. (NASDAQ:EXEL)

Susquehanna Fundamental Investments LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 361,998 shares of the biotechnology company's stock, valued at approximately $12,055,000. Susquehanna Fundamental Investments LLC owned approximately 0.13% of Exelixis as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the company. Invesco Ltd. increased its holdings in shares of Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after acquiring an additional 3,001,204 shares during the last quarter. Norges Bank acquired a new position in Exelixis in the fourth quarter valued at approximately $94,867,000. Arrowstreet Capital Limited Partnership increased its stake in Exelixis by 104.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock valued at $105,208,000 after purchasing an additional 1,613,482 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in Exelixis by 10.2% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock worth $254,110,000 after purchasing an additional 708,312 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after buying an additional 704,786 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Trading Up 1.8 %

Shares of Exelixis stock traded up $0.71 on Friday, reaching $39.60. 727,947 shares of the stock were exchanged, compared to its average volume of 2,157,326. The firm has a market capitalization of $10.91 billion, a PE ratio of 22.34, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The business has a fifty day moving average price of $36.90 and a two-hundred day moving average price of $34.96.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Guggenheim reaffirmed a "buy" rating and issued a $42.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Stephens reiterated an "equal weight" rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Piper Sandler boosted their target price on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Finally, Citigroup boosted their price objective on Exelixis from $38.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Exelixis has an average rating of "Moderate Buy" and an average target price of $37.59.

Insider Buying and Selling at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. This trade represents a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares in the company, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.